Japanese trading and investment company Sumitomo Corporation, jointly with Kazatomprom, is developing a project in nuclear medicine, aiming to extract medical isotopes from uranium, the Akorda press service reported.
President Kassym-Jomart Tokayev met with Shingo Ueno, president and CEO of Sumitomo Corporation, who reported on the joint project with Kazatomprom.
The companies are looking to extract medical radioisotopes from uranium production by-products. Tokayev acknowledged Sumitomo’s commitment to sustainable growth and responsible business practices.
During the meeting, the parties also discussed cooperation prospects, as well as the development of joint projects in transport, logistics, energy, the nuclear industry, metallurgy and oil and gas exploration.
Sumitomo Corporation — part of the Sumitomo Group — is one of Japan’s largest trading companies. In addition to its core import and export activities, the company engages in joint product development with manufacturers and invests in production and trade, including various resource deposits.
Notably, several Japanese companies are already engaged in Kazakhstani uranium mining projects. Sumitomo, jointly with Kansai, holds a stake in a company mining uranium at the West Mynkuduk Field in the Turkestan region. Furthermore, another Japanese company, Marubeni, mines uranium jointly with Kazatomprom at major deposits in the Kyzylorda region.
